2021
Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects
Chowdhury S, Bappy M, Clocchiatti-Tuozzo S, Cheeti S, Chowdhury S, Patel V. Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects. Cureus 2021, 13: e20604. PMID: 35103180, PMCID: PMC8782638, DOI: 10.7759/cureus.20604.Peer-Reviewed Original ResearchChimeric antigen receptorAdoptive cell transferGlioblastoma multiformeOncolytic virusesNanomedicine-based immunotherapyImmune-targeted therapiesResistant to current treatmentsMalignant type of brain tumorClinical trial outcomesImmunosuppressive tumorsCancer vaccinesImmunotherapy approachesImmune microenvironmentT cellsAntigen receptorCell transferImmune targetsImmunotherapyMalignant typeCurrent treatmentBrain tumorsType of brain tumorGlioblastomaClinical standpointDisease biology
2018
Oncolytic virus immunotherapy: future prospects for oncology
Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. Journal For ImmunoTherapy Of Cancer 2018, 6: 140. PMID: 30514385, PMCID: PMC6280382, DOI: 10.1186/s40425-018-0458-z.Peer-Reviewed Original ResearchConceptsOncolytic virusesSevere immune-related adverse eventsImmune-related adverse eventsAnti-tumor immune responseEarly-stage clinical trialsImmune checkpoint inhibitorsSerious adverse effectsOncolytic viral therapyLimited therapeutic responseAnti-cancer treatmentLocal target cellsCheckpoint inhibitorsSalvage therapyTolerability profileCytotoxic chemotherapyAdverse eventsImmune dysregulationOncologic careTherapeutic optionsTumor bedSuch therapyTherapeutic responseClinical trialsNovel therapiesViral therapy
2017
Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain
van den Pol AN, Mao G, Chattopadhyay A, Rose JK, Davis JN. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. Journal Of Virology 2017, 91: 10.1128/jvi.02154-16. PMID: 28077641, PMCID: PMC5331823, DOI: 10.1128/jvi.02154-16.Peer-Reviewed Original ResearchConceptsAdult mouse brainVesicular stomatitis virusVSV glycoprotein (G) geneAdult brainChimeric virusesOncolytic virusesVirus-like vesiclesChimeric vesicular stomatitis virusMouse brainSemliki Forest virusStomatitis virusPostnatal day 14 miceHealthy adult mouse brainRecombinant vesicular stomatitis virusKey immune mechanismsType I interferon responseG glycoproteinI interferon responseInterferon-stimulated genesDay 14 miceInfluenza H5N1 virusGlycoprotein geneNeurotropic natureIntranasal inoculationWild-type vesicular stomatitis virus
2012
Highly Attenuated Recombinant Vesicular Stomatitis Virus VSV-12′GFP Displays Immunogenic and Oncolytic Activity
van den Pol A, Davis J. Highly Attenuated Recombinant Vesicular Stomatitis Virus VSV-12′GFP Displays Immunogenic and Oncolytic Activity. Journal Of Virology 2012, 87: 1019-1034. PMID: 23135719, PMCID: PMC3554062, DOI: 10.1128/jvi.01106-12.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGene Expression ProfilingGenes, ReporterGliomaGreen Fluorescent ProteinsHumansMiceMice, SCIDMolecular Sequence DataOncolytic VirusesRNA, ViralSequence Analysis, DNASurvival AnalysisTreatment OutcomeVaccines, AttenuatedVaccines, SyntheticVesiculovirusViral Plaque AssayViral VaccinesConceptsVesicular stomatitis virusGreen fluorescent proteinReporter geneOne-step growth curveVesicular stomatitis virus genomeAttenuated vesicular stomatitis virusCancer cellsHigh-titer antibody responsesInjection of tumorHuman cancer cellsSuppressed tumor growthRNA transcriptsOncolytic virusesIntratumoral injectionSCID micePostnatal daySafety profileFluorescent proteinTumor growthVSV-G/GFPGenesRecombinant virusesStomatitis virusImmune responseAntibody response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply